S-Biomedic

The Belgian biotech startup S-Biomedic uses a proprietary technology to source and combine beneficial bacteria directly from healthy human skin to develop break-through treatments for skin conditions. This ensures that beneficial microbes colonize the skin in the most efficient way to rebalance the microbiome and ensure a long term and sustainable treatment.
S-Biomedic was acquired by Beiersdorf in 2022
Verve Ventures first invested in S-Biomedic’s Series A financing round alongside Beiersdorf in 2018. Verve’s team has supported S-Biomedic on its journey to a successful exit.
Founders / Management Veronika Oudova, Bernhard Pätzold
Sectors Health & Bio, Biotech, Cosmetics, Microbiome
Located in Belgium
Co-Investors Beiersdorf, DSM, Johnson & Johnson Innovation, CG Health Ventures
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.